BioNTech and Genentech halt Phase 2 trial of individualized mRNA cancer shot
BioNTech and Genentech discontinued a Phase 2 trial of their personalized mRNA cancer vaccine. The move comes shortly after Moderna and Merck reported encouraging data for their own mRNA vaccine in a different cancer setting. BioNTech did not specify the reason for the termination.
Related stories
Personalized mRNA vaccine hits Phase 3 goal in Merck-Moderna trial · Cancer research
Moderna's Cancer Vaccine Success May Hinge on a Secret Algorithm · Drug development
Melanoma Vaccine Shows Promise Amid Scrutiny of Chinese Trials · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine.” Browse more stories.